
ENGN Stock Forecast & Price Target
ENGN Analyst Ratings
Bulls say
enGene Holdings Inc. is positioned for significant growth within the market, particularly due to its dually derived chitosan (DDX) gene delivery platform, which has received RMAT designation, enhancing its potential to capture substantial market share in community practice settings. The company’s ongoing LEGEND study indicates additional commercial opportunities, with potential market expansion into earlier disease stages and active surveillance through various cohorts that could broaden its addressable market. Additionally, while research and development expenses rose to $22.6 million in the third quarter of 2025, a considerable increase from $11.5 million the previous year, this investment underscores the company's commitment to advancing its clinical programs and ultimately increasing its market presence.
Bears say
The financial outlook for enGene Holdings Inc. appears negative primarily due to the potential for regulatory approval delays, which could adversely affect the company's share price and investor confidence. Additionally, the operational challenges associated with TAR-200, including a significant procedural burden and a notable rate of serious adverse events (SAE), may hinder its market acceptance and uptake. These factors, combined with the competitive landscape, suggest that the company's commercial prospects could be compromised, further impacting its financial performance.
This aggregate rating is based on analysts' research of Engene Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
ENGN Analyst Forecast & Price Prediction
Start investing in ENGN
Order type
Buy in
Order amount
Est. shares
0 shares